Literature DB >> 2494117

Inhibition by normal human serum of Mycobacterium avium multiplication in cultured human macrophages.

A J Crowle1, P Poche.   

Abstract

Normal human serum used as a protein supplement in RPMI 1640 medium inhibited growth in blood-derived human macrophages (MP) of virulent Mycobacterium avium serovars 4 and 8, derived from patients with acquired immunodeficiency syndrome, but not virulent Mycobacterium tuberculosis. A defined serum substitute (SS) promoted the intramacrophage growth of M. avium but not of M. tuberculosis. The effects of serum or SS were measured by counting viable bacteria in lysates of the MP at 0, 4, and 7 days after their infection by the bacteria. Neither serum nor SS inhibited or enhanced M. avium growth in the absence of MP. The results suggest that a nutrient essential for intracellular replication of M. avium is made by MP from a pronutrient present in both SS and serum and that something in serum inhibits MP conversion of the pronutrient to nutrient. This inhibition may be an important mechanism of native resistance against M. avium in normal people.

Entities:  

Mesh:

Year:  1989        PMID: 2494117      PMCID: PMC313272          DOI: 10.1128/iai.57.4.1332-1335.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

Review 1.  Immunological approach for control of Mycobacterium avium-intracellulare infections in AIDS-an hypothesis.

Authors:  M G Deo
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-09

Review 2.  Role of macrophages in lipid metabolism.

Authors:  B A Kottke
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 3.  Mycobacterium avium complex infection.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages.

Authors:  A J Crowle; E J Ross; M H May
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

5.  Factors that affect the cell cycle of Mycobacterium avium.

Authors:  C McCarthy; P Ashbaugh
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

6.  Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.

Authors:  A J Crowle; N Elkins; M H May
Journal:  Am Rev Respir Dis       Date:  1988-05

7.  Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages.

Authors:  A J Crowle; A Y Tsang; A E Vatter; M H May
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

8.  Maximum growth rate of Mycobacterium avium in continuous culture or chronically infected BALB/c mice.

Authors:  C M McCarthy; M A Taylor; M W Dennis
Journal:  Microbios       Date:  1987

9.  Characterization of biological response modifier release by human monocytes cultured in suspension in serum-free medium.

Authors:  H C Stevenson; E Schlick; R Griffith; M A Chirigos; R Brown; J Conlon; D J Kanapa; R K Oldham; P Miller
Journal:  J Immunol Methods       Date:  1984-05-25       Impact factor: 2.303

  9 in total
  10 in total

1.  Drug effects on intracellular mycobacteria determined by mass spectrometric analysis of the Na(+)-to-K+ ratios of individual bacterial organisms.

Authors:  M Wiese; U Seydel
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Fluorescent acid-fast microscopy for measuring phagocytosis of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum by Tetrahymena pyriformis and their intracellular growth.

Authors:  E D Strahl; G E Gillaspy; J O Falkinham
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

3.  Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages.

Authors:  Y Cohen; C Perronne; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

4.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

5.  Characterization of inhibition of Mycobacterium avium replication in macrophages by normal human serum.

Authors:  G S Douvas; M H May; E Ross; A J Crowle
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

6.  Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic.

Authors:  A J Crowle; R Dahl; E Ross; M H May
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

7.  Defects in sera from acquired immunodeficiency syndrome (AIDS) patients and from non-AIDS patients with Mycobacterium avium infection which decrease macrophage resistance to M. avium.

Authors:  A J Crowle; D L Cohn; P Poche
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

8.  Comparison of the abilities of Mycobacterium avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects.

Authors:  A J Crowle; E R Ross; D L Cohn; J Gilden; M H May
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

9.  Mycobacterium avium-M. intracellulare binds to the integrin receptor alpha v beta 3 on human monocytes and monocyte-derived macrophages.

Authors:  S P Rao; K Ogata; A Catanzaro
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

Review 10.  Regulation of the expression of proinflammatory cytokines induced by SARS-CoV-2.

Authors:  Xiang-Ning Zhang; Long-Ji Wu; Xia Kong; Bi-Ying Zheng; Zhe Zhang; Zhi-Wei He
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.